T2 BIOSYSTEMS Forum: Community User: Delonghii

Wunschkurse wäre schön😂 @kngnssr Falls du in T2 invstieren möchtest,würde ich an Deiner Stelle nicht mehr lange warten.Sollten morgen gute News kommen,werden wir den Dollar ganz entspannt durchbrechen und dann ist zwischen 1-5 Dollar alles möglich.

Gibt's das auch Wunschkurs.

Geh aber EVTL auch bei 0,70 rein

0,60

@kngnssr Was ist Dein Wunschkurs?

Ich hoffe die Aktie fällt endlich nochmal, brauche Einkaufkurse

@Kasi77 Morgen findet ein Webinar statt.News🍀

Seh ich genauso wie du . Fängt ja gut an hier

Ich bleibe bei meiner Meinung und sehe hier etwas sehr Großes auf uns zukommen 🍀🍀🍀

LEXINGTON, Mass., May 19, 2020 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens, today announced it won the “Best New Technology Solution - Diagnostics" award for its T2Bacteria® Panel solution in the fourth annual MedTech Breakthrough Awards program. The awards program, which received thousands of nominations from companies across the globe, “recognizes the top companies, people, platforms and products in the health, fitness and medical technology industries today,” according to its website. “We’re honored to be recognized by the MedTech Breakthrough Awards and grateful to the judges who recognize the importance of rapid identification of sepsis-causing pathogens in order to effectively and efficiently treat patients with bloodstream infections, which can lead to sepsis,” said John Sperzel, President and Chief Executive Officer of T2 Biosystems. Sperzel continued, “According to the Centers for Disease Control and Prevention, each year at least 1.7 million adults in America develop sepsis and nearly 270,000 Americans die as a result. But, with swift diagnosis and treatment, which our T2Bacteria Panel helps facilitate, we can help reduce these numbers for patients with bloodstream infections and improve patient outcomes.” The T2Bacteria Panel, which was FDA cleared in May 2018, can detect sepsis-causing bacterial pathogens directly from whole blood in three to five hours, without the need to wait for a blood culture, which typically takes days to provide results and is not as sensitive. By providing quicker results, the T2Bacteria Panel can help clinicians start patients on the right therapy sooner, which can lead to a series of potential benefits, including improved patient outcomes, better management of antibiotics, reduced length of stay in the hospital and more.   The MedTech Breakthrough Award is one more addition to the Company’s growing list of accolades and milestones. Most recently, T2 Biosystems announced it was awarded an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the country, covering its T2Dx® Instrument, as well as the T2Bacteria and T2Candida® Panels.

T2 Biosystems’ Bacteria Panel Wins “Best New Technology Solution - Diagnostics" Award in MedTech Breakthrough Awards Achievement Underscores the Clinical Value of Company’s Rapid Diagnostic Test for Sepsis-causing Bacterial Pathogens in Bloodstream

Tvst83 welche Neuigkeiten

Soweit ich weiß nein,aber morgen gibts evtl positive Neuigkeiten.Pre 15%👍🏽🍀

1$$ wir kommen...

Es gibt aber noch keine Serienproduktion richtig?

Falsche Gruppe